Proteome rockets on Alzheimer's blood test
Pharma group Proteome Sciences has had a strong morning on the markets after announcing success in its project to develop better diagnostic tools for Alzheimer's disease.
Pharma group Proteome Sciences has had a strong morning on the markets after announcing success in its project to develop better diagnostic tools for Alzheimer's disease.
A study of 1,000 patients has shown three distinct "biomarkers" in people's blood which can discriminate between mild "cognitive impairment" (a syndrome often preceding Alzheimer's), Alzheimer's itself and control groups who do not have the condition.
Proteome Sciences is filing patents for the "panels" in the blood that contain the biomarkers.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
It is estimated that 60% of people with Alzheimer's disease have not been properly diagnosed and therefore are not being given the correct drugs and care.
The capability to distinguish between different levels of the disease will enable drug developers to improve patient care and people with mild symptoms are likely to benefit the most from new disease-modifying drugs.
The key is that Proteome may be able to develop a simple blood test to determine progression of Alzheimer's as opposed to the current diagnostic methods of invasive lumbar punctures or expensive MRI scans.
Presenting the data at a conference in Melbourne, Australia, Professor Simon Lovestone, who has worked with Proteome for the National Institute for Health Research said: "As new treatments for Alzheimer's disease are being developed, there is an increasing need for accurate and accessible markers of disease severity and progression. We will move quickly to support the development of clinical tests based on these biomarker panels."
Shares in Proteome had risen 8.85% by 11:08.
BS
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Banks given additional 72 hours to investigate suspicious payments
New rules will allow banks to pause suspicious payments for longer, giving them time to investigate cases of potential fraud
By Katie Williams Published
-
What financial support can you get if you are suffering with long-term illness?
Health is wealth and more important than any material riches. But too often, long-term illness brings financial worries of its own. What financial support can you get if you are ill?
By Katie Williams Published